Verrica Pharmaceuticals Inc. (VRCA) Debt Components
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term DebtUSD $0.00; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-09-30: Long-term Debt, Current MaturitiesUSD $12.46M; Long-term DebtUSD $21.62M; Long-Term Debt, Maturity, Year OneUSD $15.28M; Long-Term Debt, Maturity, Year TwoUSD $15.00M.
- 2025-06-30: Long-term Debt, Current MaturitiesUSD $12.67M; Long-term DebtUSD $24.58M; Long-Term Debt, Maturity, Year OneUSD $15.33M; Long-Term Debt, Maturity, Year TwoUSD $15.00M.
- 2025-03-31: Long-term Debt, Current MaturitiesUSD $12.82M; Long-term DebtUSD $27.81M; Long-Term Debt, Maturity, Year OneUSD $15.32M; Long-Term Debt, Maturity, Year TwoUSD $15.00M.
Verrica Pharmaceuticals Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Commitment Fee Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Short-term Debt USD | Debt, Current USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $12.46M | $21.62M | $15.28M | $15.00M | $8.75M | (m) | $3.89M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $12.67M | $24.58M | $15.33M | $15.00M | $8.75M | (m) | $7.80M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $12.82M | $27.81M | $15.32M | $15.00M | $8.75M | (m) | $11.76M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $12.94M | $30.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $15.72M | $15.33M | $15.00M | $8.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $43.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $42.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $500.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-05-06 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $42.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $42.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $42.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-07-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.00% | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2022-07-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.80M |
| 2022-06-30 | (m) | (m) | (m) | $33.33M | $6.67M | (m) | (m) | (m) | (m) | $42.29M | (m) | (m) | $40.00M |
| 2022-03-31 | (m) | (m) | $33.33M | $6.67M | (m) | (m) | (m) | (m) | (m) | $42.00M | (m) | (m) | $40.00M |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $41.69M | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $15.00M | $20.00M | $5.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $40.00M |
| 2021-09-30 | (m) | (m) | $6.67M | $26.67M | $6.67M | (m) | (m) | (m) | (m) | $41.35M | (m) | (m) | $40.00M |
| 2021-06-30 | (m) | (m) | $6.67M | $26.67M | $6.67M | (m) | (m) | (m) | (m) | $41.01M | (m) | (m) | $40.00M |
| 2021-03-31 | (m) | (m) | $6.67M | $26.67M | $6.67M | (m) | (m) | (m) | (m) | (m) | $40.67M | (m) | $40.00M |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $35.31M | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $35.31M | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $13.12M | $17.50M | $4.38M | (m) | (m) | (m) | (m) | (m) | (m) | $35.00M |
| 2020-09-30 | (m) | (m) | (m) | $13.12M | $17.50M | $4.38M | (m) | (m) | (m) | (m) | $34.98M | (m) | $35.00M |
| 2020-06-30 | $34.72M | (m) | (m) | $13.12M | $17.50M | $4.38M | (m) | (m) | (m) | (m) | (m) | (m) | $35.00M |
| 2020-03-31 | (m) | $34.43M | (m) | (m) | $13.12M | $17.50M | (m) | (m) | (m) | (m) | (m) | $4.38M | $35.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |